CoChat

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis

Teschke, Rolf, Danan, Gaby · 2020 · Medicines
Cited by 77

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robust causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method) as diagnostiinjuryc algorithm. The purpose of this analysis was to evaluate the worldwide use of RUCAM in iDILI and HILI cases. Methods: The PubMed database (1993–30 June 2020) was searched for articles by using the following key terms: Roussel Uclaf Causality Assessment Method; RUCAM; Idiosyncratic drug induced liver injury; iDILI; Herb induced liver injury; HILI. Results: Considering reports published worldwide since 1993, our analysis showed the use of RUCAM for causality assessment in 95,885 cases of liver injury including 81,856 cases of idiosyncratic DILI and 14,029 cases of HILI. Among the top countries providing RUCAM based DILI cases were, in decreasing order, China, the US, Germany, Korea, and Italy, with China, Korea, Germany, India, and the US as the top countries for HILI. Conclusions: Since 1993 RUCAM is certainly the most widely used method to assess causality in IDILI and HILI. This should encourage practitioner, experts, and regulatory agencies to use it in order to reinforce their diagnosis and to take sound decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/medicines7100062

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 242

  1. Ke, L., Lu, C., Shen, R., Lu, T., Ma, B., and Hua, Y. (2020). Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010–2019). Front. Pharmacol., in press. · DOI · Paper page
  2. Uetrecht, 2019, Mechanistic studies of idiosyncratic DILI: Clinical implications, Front. Pharmacol., 10, 837, 10.3389/fphar.2019.00837 · DOI
  3. Teschke, R., and Uetrecht, J. (2020). Mechanism of idiosyncratic drug induced liver injury (DILI): Unresolved basic issues. Ann. Transl. Med., In special issue: Unresolved basic issues in hepatology, guest editors Ralf Weiskirchen & Wolfgang Stremmel. · DOI · Paper page
  4. James, K., and David, C. (2018). Drug-Induced Liver Toxicity, Springer Protocols, Springer Nature.
  5. James, K., David, C.C., Minjun, C., and Yvonne, W. (2018). Causality assessment methods in drug-induced liver injury. Drug-Induced Liver Toxicity, Springer Nature. Chapter 27.
  6. Teschke, R., Danan, G., and Lewis, J.H. (2019). Special issue: Clinical drug induced liver injury: Current diagnostic and mechanistic challenges, guest editors: Rolf Teschke, Gaby Danan & James H. Lewis. Front. Pharmacol., Available online: https://www.frontiersin.org/research-topics/9104/clinical-drug-induced-liver-injury-current-diagnostic-and-mechanistic-challenges.
  7. Sarges, 2016, Drug-induced liver injury: Highlights from a review of the 2015 literature, Drug Saf., 39, 561, 10.1007/s40264-016-0427-8 · DOI · Paper page
  8. Shahbaz, 2017, Highlights of drug- and herb-induced liver injury in the literature from 2016, How best to translate new information into clinical practice?, Exp. Opin. Drug Metab. Toxicol., 13, 935, 10.1080/17425255.2017.1362391 · DOI · Paper page
  9. Real, 2019, Drug-induced liver injury: Highlights of the recent literature, Drug Saf., 42, 365, 10.1007/s40264-018-0743-2 · DOI · Paper page
  10. Rosenberg, 2020, Selected highlights from the recent literature of newly reported herbal and dietary supplement-induced liver injury, Adv. Res. Gastroenterol. Hepatol., 15, 555904, 10.19080/ARGH.2020.15.555904 · DOI
  11. Teschke, 2019, Idiosyncratic DILI: Analysis of 46, 266 cases assessed for causality by RUCAM and published from 2014 to early 2019, Front. Pharmacol., 10, 730, 10.3389/fphar.2019.00730 · DOI · Paper page
  12. Teschke, R., Eickhoff, A., Schulze, J., and Danan, G. (2020). Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): An overview. Transl. Gastroenterol. Hepatol., in press. · DOI
  13. Danan, G., and Teschke, R. (2016). RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17. · DOI · Paper page
  14. Danan, 2018, Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?, Drug Saf., 41, 735, 10.1007/s40264-018-0654-2 · DOI · Paper page
  15. Danan, 2019, Roussel Uclaf Causality Assessment Method for drug-induced liver injury: Present and Future, Front. Pharmacol., 10, 853, 10.3389/fphar.2019.00853 · DOI · Paper page
  16. Teschke, 2020, Editorial. DILI, HILI, RUCAM algorithm, and AI, the Artificial Intelligence: Provocative issues, progress, and proposals, Arch. Gastroenterol. Res., 1, 4
  17. Hayashi, P.H. (2016). Drug-Induced Liver Injury Network causality assessment: Criteria and experience in the United States. Int. J. Mol. Sci., 17. · DOI · Paper page
  18. Teschke, 2015, Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment, Gastroenterology, 148, 1271, 10.1053/j.gastro.2015.04.027 · DOI
  19. Teschke, R., Eickhoff, A., Brown, A.C., Neuman, M.G., and Schulze, J. (2020). Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted Letter of Support. Int. J. Mol. Sci., 21. · DOI · Paper page
  20. Nikolaos, T. (2020). Acetaminophen syn. paracetamol: Acute liver injury and acute on chronic liver failure with case analysis and causality assessment using RUCAM. Liver Failure: Acute and Acute on Chronic, Springer Nature.
  21. Bessone, F., Hermandez, N., Lucena, M.I., and Andrade, R.J. (2016). The Latin American DILI registry experience: A successful ongoing collaborative strategic initiative. Int. J. Mol. Sci., 17. · DOI · Paper page
  22. Bessone, 2019, When the creation of a consortium provides useful answers: Experience of The Latin American DILI Network (LATINDILIN), Clin. Liver Dis., 13, 51, 10.1002/cld.778 · DOI · Paper page
  23. Colaci, 2019, Idiosyncratic drug-induced acute liver failure: A challenging and distressing scenario, Curr. Drug Saf., 14, 94, 10.2174/1574886314666190215115434 · DOI
  24. Saturansky, 2019, Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?, Ann. Hepatol., 18, 765, 10.1016/j.aohep.2019.01.011 · DOI
  25. Lin, 2014, Drug-induced hepatotoxicity: Incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients, Liver Int., 34, 576, 10.1111/liv.12278 · DOI
  26. Ahmed, 2015, Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy, BMJ Case Rep., 2015, bcr2014208102, 10.1136/bcr-2014-208102 · DOI · Paper page
  27. Laube, 2019, An unwanted complement: Rare case of potential liver injury induced by an interaction between ginseng and atorvastatin, Br. J. Clin. Pharm., 85, 1612, 10.1111/bcp.13927 · doi:10.1111/bcp.13927
  28. Worland, 2020, Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: The IDLE study, Ann. Gastroenterol., 33, 162
  29. Sridharan, K., Al Daylami, A., Ajjawi, R., and Al Ajooz, H.A.M. (2020). Drug-induced liver injury in critically ill children taking antiepileptic drugs: A retrospective study. Curr. Ther. Res., in press. · DOI
  30. Becker, 2019, Drug and herb-induced liver injury: A critical review of Brazilian cases with proposals for the improvement of causality assessment using RUCAM, Ann. Hepatol., 18, 742, 10.1016/j.aohep.2019.03.010 · DOI
  31. Yan, 2006, Rofecoxib-induced hepatotoxicity: A forgotten complication of the coxibs, Can. J. Gastroenterol., 20, 351, 10.1155/2006/356434 · DOI
  32. Nhean, 2019, Probable hepatotoxicity with dolutegravir: Report of two cases and review of the literature, Aids, 33, 1261, 10.1097/QAD.0000000000002191 · doi:10.1097/qad.0000000000002191
  33. Hou, 2012, Hospital admissions for drug-induced liver injury: Clinical features, therapy, and outcomes, Cell Biochem. Biophys., 64, 77, 10.1007/s12013-012-9373-y · DOI
  34. Lv, 2012, NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population, Ann. Hepatol., 11, 700, 10.1016/S1665-2681(19)31446-2 · DOI
  35. Hao, 2014, RUCAM scale-based diagnosis, clinical features and prognosis of 140 cases of drug-induced liver injury, Chin. J. Hepatol., 22, 938
  36. Ou, 2015, Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital, SpringerPlus, 4, 802, 10.1186/s40064-015-1600-8 · DOI · Paper page
  37. Zhu, 2015, Causes, features, and outcomes of drug-induced liver injury in 69 children from China, Gut Liver, 9, 525, 10.5009/gnl14184 · DOI
  38. Lu, 2016, Clinical characteristics of drug-induced liver injury and related risk factors, Exp. Med., 12, 2606, 10.3892/etm.2016.3627 · DOI
  39. Yang, 2016, Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis, World J. Gastroenterol., 22, 7579, 10.3748/wjg.v22.i33.7579 · DOI
  40. Zhu, 2016, Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients, J. Gastroenterol. Hepatol., 31, 1476, 10.1111/jgh.13323 · DOI · Paper page
  41. Naiqiong, 2017, A multicenter and randomized controlled trial of Bicyclol in the treatment of statin-induced liver injury, Med. Sci. Monit., 23, 5760, 10.12659/MSM.904090 · DOI
  42. Li, X.L., Liu, X., Song, Y., Hong, R.T., and Shi, H. (2018). Suspected drug-induced liver injury associated with iguratimod: A case report and review of the literature. BMC Gastroenterol., 18. · DOI
  43. Song, 2018, Posaconazole-associated severe hyperbilirubinemia in acute myeloid leukemia following chemotherapy: A case report, World J. Clin. Cases, 6, 1206, 10.12998/wjcc.v6.i16.1206 · DOI
  44. Tao, 2018, Genetic polymorphisms of UGT 1A1 and susceptibility to anti-tuberculosis drug-induced liver injury: A RUCAM-based case-control study, Int. J. Immunopathol. Pharm., 32, 1, 10.1177/2058738418816288 · DOI
  45. Liao, 2019, A rare case of cefapime-induced cholestatic liver injury, Tzu Chi Med. J., 31, 124, 10.4103/tcmj.tcmj_151_18 · DOI
  46. Xing, 2019, Assessment of cholestasis in drug-induced liver injury by different methods, Medicine, 98, e14399, 10.1097/MD.0000000000014399 · DOI
  47. Ma, 2020, Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database, J. Clin. Pharm., 45, 204
  48. Tao, B., Yang, M., Chen, H., Pan, H., Liu, W., Yi, H., and Tang, S. (2020). Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population. J. Clin. Pharm. · DOI
  49. Wang, S., Shangguan, Y., Ding, C., Li, P., Ji, Z., Shao, J., Fang, H., Yang, M., Shi, P., and Wu, J. (2020). Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury. J. Int. Med. Res., 48. · DOI
  50. Yang, 2019, Comparison of different liver test thresholds for drug-induced liver injury: Updated RUCAM versus other methods, Front. Pharmacol., 10, 816, 10.3389/fphar.2019.00816 · DOI · Paper page
  51. Restrepo, 2013, Abendazole-induced liver injury: A case report, Colomb. Med., 44, 118, 10.25100/cm.v44i2.1021 · DOI
  52. Amariles, 2019, Epidemiology of drug-induced liver injury in a university hospital from Colombia: Updated RUCAM being used for prospective causality assessment, Ann. Hepatol., 18, 501, 10.1016/j.aohep.2018.11.008 · DOI
  53. Alhaddad, 2020, Presentations, causes and outcomes of drug-induced liver injury in Egypt, Sci. Rep., 10, 5124, 10.1038/s41598-020-61872-9 · DOI · Paper page
  54. Danan, 1993, Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge, J. Clin. Epidemiol., 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  55. Arotcarena, 2004, Pioglitazone-induced acute severe hepatitis, Gastroenterol. Clin. Biol., 28, 609
  56. Moch, 2012, Etifoxine-induced acute hepatitis: A case series, Clin. Res. Hepatol. Gastroenterol., 36, e85, 10.1016/j.clinre.2012.04.002 · DOI
  57. Carrier, 2013, Acute liver toxicity due to methylprednisolone: Consider this diagnosis in the context of autoimmunity, Clin. Res. Hepatol. Gastroenterol., 37, 100, 10.1016/j.clinre.2012.10.015 · DOI
  58. Ripault, 2013, Crizotinib-induced acute hepatitis: First case with relaps after reintroduction with reduced dose, Clin. Res. Hepatol. Gastroenterol., 37, e21, 10.1016/j.clinre.2012.10.003 · DOI
  59. Dumortier, 2017, Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey, Clin. Res. Hepatol. Gastroenterol., 41, 497, 10.1016/j.clinre.2017.03.008 · DOI
  60. Meunier, 2018, Recent advances in hepatotoxicity of non steroidal anti-inflammatory drugs, Ann. Hepatol., 17, 187, 10.5604/01.3001.0010.8633 · DOI
  61. Douros, 2014, Flupirtine-induced liver injury-Seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database, Eur. J. Clin. Pharm., 70, 453, 10.1007/s00228-013-1631-4 · DOI
  62. Douros, 2014, Drug-induced liver injury: Results from the hospital-based Berlin Case-Control Surveillance Study, Br. J. Clin. Pharm., 79, 988, 10.1111/bcp.12565 · DOI · Paper page
  63. Buechter, 2018, Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients, World J. Gastroenterol., 24, 1410, 10.3748/wjg.v24.i13.1410 · DOI
  64. Dragoi, 2018, Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac, Front. Pharmacol., 9, 699, 10.3389/fphar.2018.00699 · DOI · Paper page
  65. Teschke, 2018, Review: Drug induced liver injury with analysis of alternative causes as confounding variables, Br. J. Clin. Pharm., 84, 1467, 10.1111/bcp.13593 · DOI
  66. Teschke, 2018, Review. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method, Expert Opin. Drug Metab. Toxicol., 14, 1169
  67. Weber, 2019, Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis, Liver Int., 39, 1906, 10.1111/liv.14195 · DOI · Paper page
  68. Jacobsen, 2012, Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing, J. Hepatol., 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
  69. Hoofnagle, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
  70. Harugeri, 2009, Montelukast induced acute hepatocellular injury, J. Postgrad. Med., 55, 141, 10.4103/0022-3859.52850 · DOI
  71. Devarbhavi, 2010, Single center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality, Am. J. Gastroenterol., 105, 2396, 10.1038/ajg.2010.287 · DOI · Paper page
  72. Taneja, 2017, Acute liver failure due to Etodolac, a selective cycloxygenase- 2 (COX-2) inhibitor non-steroidal anti-inflammatory drug established by RUCAM-based causality assessment, Ann. Hepatol., 16, 818, 10.5604/01.3001.0010.2829 · DOI
  73. Dutta, 2020, Haloperidol induced hepatotoxicity: A case report, Ann. Clin. Case Rep., 5, 1827
  74. Kulkarni, 2020, Steroids as rescue therapy for vitamin A-induced acute liver failure, BMJ Case Rep. CP, 13, e233902, 10.1136/bcr-2019-233902 · DOI
  75. Gluck, 2011, Acute amiodarone liver toxicity likely due to ischemic hepatitis, Isr. Med. Assoc. J., 13, 748
  76. Rigato, 2007, Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1, Nat. Clin. Pr. Gastroenterol. Hepatol., 4, 43
  77. Licata, 2010, Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication, Dig. Liver Dis., 42, 143, 10.1016/j.dld.2009.06.009 · DOI
  78. Abenavoli, 2013, Severe hepatitis by cyproterone acetate: Role of corticosteroids. A case report, Ann. Hepatol., 1, 152, 10.1016/S1665-2681(19)31399-7 · DOI
  79. Ferrajolo, 2017, Antibiotic-induced liver injury in paediatric outpatients: A case-control study in primary care databases, Drug Saf., 40, 305, 10.1007/s40264-016-0493-y · DOI
  80. Licata, 2017, A focus on epidemiology of drug-induced liver injury; analysis of a prospective cohort, Eur. Rev. Pharm. Sci., 21, 112
  81. Giacomelli, A., Rusconi, S., Falvella, F.S., Oreni, M.L., Cattaneo, D., Cozzi, V., Renisi, G., Monge, E., Cheli, S., and Clementi, E. (2018). Clinical and genetic determinants of nevirapine plasma through concentration. SAGE Open Med., 6. · DOI
  82. Licata, 2018, Rivaroxaban-induced hepatotoxicity: Review of the literature and report of new cases, Eur. J. Gastroenterol. Hepatol., 30, 226, 10.1097/MEG.0000000000001030 · DOI
  83. Lovero, 2018, A case of severe transaminase elevation following a single Ustekinumab dose with remission after drug withdrawal, Curr. Drug Saf., 13, 221, 10.2174/1574886313666180719165212 · doi:10.2174/1574886313666180719165212
  84. Masumoto, 2003, Diagnosis of drug-induced liver injury in Japanese patients by criteria of the Consensus Meetings in Europe, Hepatol. Res., 25, 1, 10.1016/S1386-6346(02)00148-1 · DOI
  85. Hanatani, 2014, A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale, Pharm. Drug Saf., 23, 984
  86. Niijima, 2017, Drug-induced liver injury caused by Ipragliflozin administration with causality established by a positive lymphocyte transformation test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A case report, Ann. Hepatol., 16, 308, 10.5604/16652681.1231594 · DOI
  87. Ji, 2017, A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism: A case report, Medicine, 96, e9093, 10.1097/MD.0000000000009093 · DOI
  88. Aiso, 2019, Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan, Hepatol. Res., 49, 105, 10.1111/hepr.13288 · DOI · Paper page
  89. Kishimoto, 2019, Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: A case report, SAGE Open Med. Cases Rep., 7, 1
  90. Hiraki, 2020, An unusual case of acute liver failure caused by adjuvant oral Tegafur-Uracil with folinate therapy for colon cancer patient: A case report, J. Gastrointest. Cancer, 51, 296, 10.1007/s12029-019-00228-7 · DOI
  91. Kakisaka, 2019, Unfavorable prognosis of patients with acute liver injury due to drug-induced liver injury and acute exacerbation of hepatitis B virus infection, Hepatol. Res., 49, 1286, 10.1111/hepr.13397 · DOI
  92. Choi, 2008, Acute drug-induced hepatitis caused by albendazole, J. Korean Med. Sci., 23, 903, 10.3346/jkms.2008.23.5.903 · DOI · Paper page
  93. Suk, 2012, A prospective nationwide study of drug-induced liver injury in Korea, Am. J. Gastroenterol., 107, 1380, 10.1038/ajg.2012.138 · DOI · Paper page
  94. Son, 2015, Drug-induced liver injury by Western medication, J. Int. Korean Med., 36, 69
  95. Woo, 2015, Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center, Phytomedicine, 22, 1201, 10.1016/j.phymed.2015.10.002 · DOI · Paper page
  96. Kwon, 2019, Nimesulide-induced hepatotoxicity: A systemic review and meta-analysis, PLoS ONE, 14, e0209264, 10.1371/journal.pone.0209264 · DOI
  97. Thalha, 2018, Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease, JGH Open, 2, 242, 10.1002/jgh3.12083 · DOI
  98. 2018, Non-cholestatic acute hepatitis following Candesartan administration, Br. J. Clin. Pharm., 84, 204, 10.1111/bcp.13406 · DOI
  99. Essaid, 2010, Cholestatic acute hepatitis induced by tadalafil (Cialis®), Gastroenterol. Clin. Biol., 34, e1, 10.1016/j.gcb.2010.01.001 · DOI
  100. Costa-Moreira, P., Gaspar, R., Pereira, P., Lopes, S., Canao, P., Lopes, J., Carneiro, F., and Macedo, G. (2020). Role of liver biopsy in the era of clinical prediction scores for “drug-induced liver injury” (DILI): Experience of a tertiary referral hospital. Virchows Arch. · DOI
  101. Alqrinawi, S.H., Akbar, N., AlFaddag, H., Akbar, S., Akbar, L., Butt, S.A., and Aljawad, M. (2019). Menotrophin induced autoimmune hepatitis. Case Rep. Gastrointest. Med. · DOI
  102. Miljkovic, 2011, Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity, Pharm. Drug Saf., 20, 272
  103. Miljkovic, 2012, Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity, J. Clin. Pharm., 37, 196
  104. Wai, 2006, Presentation of drug-induced liver injury in Singapore, Singap. Med. J., 47, 116
  105. Stricker, 1996, Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid, Arch. Int. Med., 156, 1327, 10.1001/archinte.1996.00440110099013 · DOI · Paper page
  106. Andrade, 2005, Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
  107. Lucena, 2008, Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury, Aliment. Pharm., 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
  108. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
  109. Lucena, 2011, Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis, J. Hepatol., 55, 820, 10.1016/j.jhep.2010.12.041 · DOI · Paper page
  110. Stephens, 2015, on behalf of the Spanish DILI Registry and the SLatinDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment. Pharm., 41, 116, 10.1111/apt.13023 · DOI · Paper page
  111. Tong, 2015, Liver transplant in a patient under methylphenidate therapy: A case report and review of the literature, Case Rep. Pediatr., 2015, 437298
  112. Stephens, 2016, Spanish DILI registry. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J. Hepatol., 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  113. Conde, 2018, Non-invasive prediction of NAFLD severity: A comprehensive, independent validation of previously postulated serum microRNA biomarkers, Sci. Rep., 8, 10606, 10.1038/s41598-018-28854-4 · DOI
  114. Machlab, 2019, Apixaban-induced liver injury, Rev. Esp. Enferm. Dig., 111, 161
  115. Zoubek, 2019, Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review, United Eur. Gastroenterol. J., 7, 825, 10.1177/2050640619840147 · DOI
  116. Olsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 · DOI · Paper page
  117. Klinteberg, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment. Pharm., 24, 1187, 10.1111/j.1365-2036.2006.03117.x · DOI · Paper page
  118. Kalaitzakis, 2007, Long-term follow-up of patients with mild to moderate drug-induced liver injury, Aliment. Pharm., 26, 79, 10.1111/j.1365-2036.2007.03355.x · DOI
  119. 2014, Epidemiology and risk factors for idiosyncratic drug-induced liver injury, Semin Liver Dis., 34, 115, 10.1055/s-0034-1375953 · DOI
  120. Goossens, 2013, Severe immune-mediated drug-induced liver injury linked to ibandronate: A case report, J. Hepatol., 59, 1139, 10.1016/j.jhep.2013.06.003 · DOI
  121. Russmann, 2014, Rivaroxaban postmarketing risk of liver injury, J. Hepatol., 61, 293, 10.1016/j.jhep.2014.03.026 · DOI
  122. Scalfaro, 2017, Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: The PV-RUCAM, Drug Saf., 40, 715, 10.1007/s40264-017-0541-2 · DOI · Paper page
  123. Schneider, 2017, Drug-induced autoimmune hepatitis following treatment with Zoledronic acid, Case Rep. Gastroenterol., 11, 440, 10.1159/000479314 · DOI
  124. Bertoli, 2017, Atovaquone/proguanil-induced autoimmune-like hepatitis, Hepatol. Commun., 1, 293, 10.1002/hep4.1039 · DOI
  125. Visentin, 2018, Drug-induced bile duct injury, BBA Mol. Basis Dis., 1864, 1498, 10.1016/j.bbadis.2017.08.033 · DOI
  126. Treeprasertsuk, 2010, The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents, Aliment. Pharm., 11, 1200, 10.1111/j.1365-2036.2010.04292.x · DOI
  127. Sobhonslidsuk, A., Poovorawan, K., Soonthornworasiri, N., Pangnum, W., and Phaosawasdi, K. (2016). The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: A population-base study. BMC Gastroenterol., 16. · DOI
  128. Chayanupatkul, 2020, Acute liver failure secondary to drug-induced liver injury, Clin. Liver Dis., 24, 75, 10.1016/j.cld.2019.09.005 · DOI
  129. Duzenli, 2019, Drug-induced liver injury caused by Phenprobamate: Strong probability due to repeated toxicity, Eur. J. HepatoGastroenterol., 9, 49
  130. Hussaini, 2007, Antibiotic therapy: A major cause of drug-induced jaundice in southwest England, Eur. J. Gastroenterol. Hepatol., 19, 15, 10.1097/01.meg.0000250581.77865.68 · DOI
  131. Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat. Genet., 41, 816, 10.1038/ng.379 · DOI · Paper page
  132. Spraggs, 2011, HLA-DQA1*02, 01 is a major risk factor for Lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
  133. Islam, 2014, A case of anastrazole-related drug-induced autoimmune hepatitis, Clin. J. Gastroenterol., 7, 414, 10.1007/s12328-014-0512-4 · DOI
  134. Dyson, 2016, Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use, J. Hepatol., 64, 234, 10.1016/j.jhep.2015.07.041 · DOI
  135. Abbara, A., Chitty, S., Roe, J.K., Ghani, R., Collin, S.M., Ritchie, A., Kon, O.M., Dzvova, J., Davidson, H., and Edwards, T.E. (2017). Drug-induced liver injury from antituberculous treatment: A retrospective study from a large TB centre in the UK. BMC Infect. Dis., 17. · DOI · Paper page
  136. Vliegenthart, 2017, MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury, Br. J. Clin. Pharm., 83, 2027, 10.1111/bcp.13282 · DOI
  137. Fontana, 2005, Acute liver failure due to amoxicillin and amoxicillin/clavulanate, Dig. Dis. Sci., 10, 1785, 10.1007/s10620-005-2938-5 · DOI
  138. Lee, 2005, Hepatic findings in long-term clinical trials of ximelagatran, Drug Saf., 28, 351, 10.2165/00002018-200528040-00006 · DOI · Paper page
  139. Stojanovski, 2007, Atomoxetine-induced hepatitis in a child, Clin. Toxicol., 45, 51, 10.1080/15563650600795644 · DOI · Paper page
  140. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, J. Hepatol., 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  141. Singla, 2010, Uncommon cause of acute drug-induced liver injury following mammoplasty, Gastroenterol. Res., 3, 171
  142. Nabha, 2012, Etravirine induced severe hpersensitivity reaction and fulminant hepatitis: A case report and review of the literature, J. Aids Clin. Res., 3, 005
  143. Sprague, D., and Bamha, K. (2012). Drug-induced liver injury due to varenicline. BMC Gastroenterol., 12. · DOI
  144. Markova, 2013, Association of CYP2C9*2 with bosentan-induced liver injury, Clin. Pharm., 94, 678
  145. Marumoto, 2013, Trial and error: Investigational drug induced liver injury, a case series report, Hawaii J. Med. Public Health, 72, 30
  146. Bohm, 2014, Case report and cohort analysis of drug-induced liver injury associated with daptomycin, Antimicrob. Agents Chemother., 58, 4902, 10.1128/AAC.03157-14 · DOI
  147. Cheetham, 2014, An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data, Pharm. Drug Saf., 23, 601
  148. Lim, 2014, A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: Can causality assessment scales be utilized to identify the offending drug?, Case Rep. Pediatr., 2014, 156389
  149. Russo, 2014, Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI · Paper page
  150. Veluswamy, 2014, Adverse drug reaction: Pomalidomide-induced liver injury, Lancet, 383, 2125, 10.1016/S0140-6736(14)61030-8 · DOI
  151. Baig, 2015, Acute liver failure after initiation of rivaroxaban: A case report and review of the literature, N. Am. J. Med. Sci., 7, 407, 10.4103/1947-2714.166221 · DOI
  152. Hammerstrom, 2015, Possible Amlodipine-induced hepatotoxicity after stem cell transplant, Ann. Pharm., 49, 135
  153. Stine, 2015, Hepatic decompensation likely attributable to Simeprevir in patients with advanced cirrhosis, Dig. Dis. Sci., 60, 1031, 10.1007/s10620-014-3422-x · DOI
  154. Tang, 2015, Acute hepatocellular drug-induced liver injury from bupropion and doxycycline, ACG Case Rep. J., 3, 66, 10.14309/crj.2015.103 · DOI
  155. Unger, 2016, Ciprofloxacin exposure leading to fatal hepatotoxicity: An unusual correlation, Am. J. Case Rep., 17, 676, 10.12659/AJCR.899080 · doi:10.12659/ajcr.899080
  156. Gharia, 2017, Letrozole-induced hepatitis with autoimmune features: A rare adverse drug reaction with review of the relevant literature, Oxf. Med. Case Rep., 2017, omx074, 10.1093/omcr/omx074 · doi:10.1093/omcr/omx074
  157. Nicoletti, 2017, International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of liver injury from specific drugs or group of drugs with polymorphisms in HLA and other genes in a Genome-wide Association Study, Gastroenterology, 152, 1078, 10.1053/j.gastro.2016.12.016 · DOI · Paper page
  158. Gayam, 2018, Drug-Induced Liver Injury: An institutional case series and review of literature, J. Investig. Med. High Impact Case Rep., 6, 1
  159. Hayashi, 2018, Long-term outcomes after drug-induced liver injury, Curr. Hepatol. Rep., 17, 292, 10.1007/s11901-018-0411-0 · DOI · Paper page
  160. Patel, S., Mendler, M.H., Valasek, M.A., and Tsunoda, S.M. (2018). Drug-induced liver injury associated with the use of Everolimus in a liver transplantant patient. Case Rep. Transpl. · DOI · Paper page
  161. Shamberg, 2018, Hepatotoxicity of inflammatory bowel disease medications, J. Clin. Gastroenterol., 52, 674, 10.1097/MCG.0000000000001084 · doi:10.1097/mcg.0000000000001084
  162. Cirulli, 2019, Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury, Gastroenterology, 56, 1707, 10.1053/j.gastro.2019.01.034 · DOI · Paper page
  163. Nicoletti, 2019, International Drug-Induced Liver Injury Consortium (iDILIC). Drug-induced liver injury due to Flucloxacillin: Relevance of multiple human leukocyte antigen alleles, Clin. Pharm., 106, 245
  164. Sandritter, 2019, An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children, Sci. Rep., 9, 18090, 10.1038/s41598-019-54075-4 · DOI · Paper page
  165. Shumar, 2019, Memantine-induced liver injury with probable causality as assessed using the Roussel Uclaf Causality Assessment Method (RUCAM), ACG Case Rep. J., 6, e00184, 10.14309/crj.0000000000000184 · DOI
  166. Tsung, 2019, Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy, Aliment. Pharm., 50, 800, 10.1111/apt.15413 · DOI · Paper page
  167. Xie, 2019, Anastrozole-induced liver injury after a prolonged latency: A very rare complication of a commonly prescribed medication, BMJ Case Rep., 12, e231741, 10.1136/bcr-2019-231741 · doi:10.1136/bcr-2019-231741
  168. Ghabril, 2020, Significant medical comorbidities are associated with lower causality scores in patients presenting with suspected drug-induced liver injury, Clin. Transl. Gastroenterol., 11, e00141, 10.14309/ctg.0000000000000141 · DOI
  169. Mehershahi, 2020, Enoxaparin-induced liver injury, Case Rep. Gastroenterol., 14, 315, 10.1159/000508471 · doi:10.1159/000508471
  170. Mullins, 2020, Drug-induced liver injury (DILI) with Micafungin: The importance of causality assessment, Ann. Pharm., 54, 526
  171. Smith, 2016, Fulminant liver failure and transplantation after use of dietary supplements, Med. J. Aust., 204, 30, 10.5694/mja15.00816 · DOI
  172. Stadlbauer, 2005, Hepatotoxicity of NONI juice: Report of two cases, World J. Gastroenterol., 11, 4758, 10.3748/wjg.v11.i30.4758 · DOI · Paper page
  173. Barcelos, S.T.A., Dall’Oglio, V.M., de Araújo, A., and Schmidt Cerski, C.T. (2019). Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report. Ann. Hepatol., in press.
  174. Yuen, 2006, Traditional Chinese Medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study, Aliment. Pharm., 24, 1179, 10.1111/j.1365-2036.2006.03111.x · DOI · Paper page
  175. Cheung, 2009, Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine, Clin. Toxicol., 47, 683, 10.1080/15563650903059136 · DOI · Paper page
  176. Chau, 2011, Causality assessment of herb-induced liver injury using multidisciplinary approach and the Roussel Uclaf Causality Assessment Method (RUCAM), Clin. Toxicol., 49, 34, 10.3109/15563650.2010.537662 · DOI · Paper page
  177. Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J. Hepatol., 54, 666, 10.1016/j.jhep.2010.07.031 · DOI · Paper page
  178. Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J. Dig. Dis., 13, 33, 10.1111/j.1751-2980.2011.00552.x · DOI · Paper page
  179. Lai, 2012, Clinical and pathological features in 138 cases of drug-induced liver injury, Zhonghua Gan Zang Bing Za ZhiZhonghua Ganzangbing Zazhi Chin. J. Hepatol., 20, 185
  180. Dong, 2014, Eighteen cases of liver injury following ingestion of Polygonum multiflorum, Complement. Med., 22, 70, 10.1016/j.ctim.2013.12.008 · DOI · Paper page
  181. Gao, 2015, Blood pyrrole-protein adducts as diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome, Drug Des. Dev., 9, 4861
  182. Wang, 2015, Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum, Front. Med., 9, 457, 10.1007/s11684-015-0417-8 · DOI · Paper page
  183. Zhu, 2015, Clinical analysis of drug-induced liver injury caused by Polygonum multiflorum and its preparations, Zhongguo Zhong Xi Yi Jie He Za Zhi, 35, 1442
  184. Zhang, P., Ye, Y., Yang, X., and Jiao, Y. (2016). Systematic review on Chinese herbal medicine induced liver injury. Evid.-Based Complement. Altern. Med. · DOI · Paper page
  185. Li, 2017, Idiosyncratic drug-induced liver injury linked to Polygonum multiflorum: A case study by pharmacognosy, Chin. Integr. Med., 23, 625, 10.1007/s11655-017-2543-9 · DOI · Paper page
  186. Chow, 2019, Medicine herbs-induced liver injury from an oncological perspective with RUCAM, Integr. Cancer, 18, 1
  187. Jing, 2019, Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-Polygonum multiflorum thunbinduced liver injury: A case-control study from a specialised liver disease center in China, BMJ Open, 9, e023567, 10.1136/bmjopen-2018-023567 · DOI · Paper page
  188. Li, A., Gao, M., Zhao, N., Li, P., Zhu, J., and Li, W. (2019). Acute liver failure associated with Fructus Psoraleae: A case report and literature review. BMC Complement. Altern. Med., 19. · DOI · Paper page
  189. Ni, 2019, Polygonum multiflorum-induced liver injury: Clinical characteristics, risk factors, material basis, action mechanism and current challenges, Front. Pharmacol., 10, 1467, 10.3389/fphar.2019.01467 · DOI · Paper page
  190. Tan, 2019, RUCAM-based assessment of liver injury by xian-tian-guo (Swietenia macrophylla) seeds, a plant used for treatment of hypertension and diabetes, Ann. Hepatol., 18, 403, 10.1016/j.aohep.2019.01.003 · DOI · Paper page
  191. Zhu, 2019, Predictors of poor outcomes in 488 patients with herb-induced liver injury, Turk. J. Gastroenterol., 30, 47
  192. Gao, Y., Wang, Z., Tang, J., Liu, X., Shi, W., Qin, N., Wang, X., Pang, Y., Li, R., and Zhang, Y. (2020). New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions. Front. Med., 28. · DOI
  193. Xia, 2020, Causality assessment of skyfruit-induced liver injury using the updated RUCAM: A case report and review of the literature, J. Int. Med. Res., 48, 300060520917569, 10.1177/0300060520917569 · DOI
  194. Restrepo, 2006, Acute hepatitis due to shen-min: A herbal product derived from Polygonum multiflorum, J. Clin. Gastroenterol., 40, 629, 10.1097/00004836-200608000-00014 · DOI
  195. Parlati, 2017, Aloe vera-induced acute liver injury: A case report and literature review, Clin. Res. Hepatol. Gastroenterol., 41, e39, 10.1016/j.clinre.2016.10.002 · DOI
  196. Teschke, 2009, Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment, Ann. Hepatol., 8, 258, 10.1016/S1665-2681(19)31777-6 · DOI · Paper page
  197. Teschke, 2011, Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports, Regul. Toxicol. Pharm., 61, 282, 10.1016/j.yrtph.2011.08.008 · DOI
  198. Teschke, 2012, Suspected Greater Celandine hepatotoxicity: Liver specific causality evaluation of published case reports from Europe, Eur. J. Gastroenterol. Hepatol., 24, 270, 10.1097/MEG.0b013e32834f993f · DOI
  199. Douros, A., Bronder, E., Andersohn, F., Klimpel, A., Kreutz, R., Garbe, E., and Bolbrinker, J. (2016). Herb-induced liver injury in the Berlin Case-Control Surveillance Study. Int. J. Mol. Sci., 17. · DOI
  200. Teschke, 2015, Traditional Chinese Medicine and herbal hepatotoxicity: A tabular compilation of reported cases, Ann. Hepatol., 14, 7, 10.1016/S1665-2681(19)30796-3 · DOI · Paper page

200 of 242 shown

Cited by

See all 77

Metadata

Authors
Teschke, R., & Danan, G.
Affiliations
  • Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Teaching Hospital of the Medical Faculty of the Goethe University, D-60590 Frankfurt/Main, Germany
  • Pharmacovigilance Consultancy, F-75020 Paris, France
Venue
Medicines
Publisher
MDPI AG
Published
2020-09-29
Volume
7
Issue
10
Pages
62
ISSN
2305-6320
Cited by
77
References
13
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. https://app.cochat.ai/papers/10.3390/medicines7100062
The paper
Teschke, R., & Danan, G. (2020). Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. Medicines. https://doi.org/10.3390/medicines7100062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.